Dano Medical-B (06872): Rifaquone (TNP-2092) Administered via Intra-articular Injection for the Treatment of Prosthetic Joint Infection Completes First Patient Enrollment in Multicenter Phase IIb Clinical Trial

Zhitong Finance APP News, TenNor Therapeutics-B (06872) announced that its investigational new drug candidate rifaquinoine (TNP-2092) has completed enrollment of the first patient in a multicenter Phase IIb clinical trial for the treatment of prosthetic joint infection (PJI) via intra-articular injection. The trial aims to further evaluate the efficacy, safety, and pharmacokinetic profile of rifaquinoine (TNP-2092) in treating PJI without debridement or revision surgery, marking a key stage in the clinical development of this potentially disruptive new drug product.